#BEGIN_DRUGCARD DB00026

# AHFS_Codes:
92:00.00

# ATC_Codes:
L04AC03

# Absorption:
When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. 
Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;
Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Kineret (Amgen Inc)

# CAS_Registry_Number:
143090-92-0

# ChEBI_ID:
Not Available

# Chemical_Formula:
C759H1186N208O232S10

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>DB00026 sequence
MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG
IHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW
FLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2245913

# Description:
Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. FDA approved on November 14, 2001.

# Dosage_Forms:
Injection, solution	Subcutaneous

# Drug_Category:
Antirheumatic Agents
Immunomodulatory Agents

# Drug_Interactions:
Canakinumab	results in increased immunosuppressive effects; increases the risk of infection.
Certolizumab pegol	Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended.
Rilonacept	results in increased immunosuppressive effects; increases the risk of infection.
Thalidomide	Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided.
Tofacitinib	Avoid combination due to the potential increase in tofacitinib related adverse effects.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.

# Drug_Type:
Approved
Biotech

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.412

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
M55646

# Generic_Name:
Anakinra

# HET_ID:
Not Available

# Half_Life:
Healthy subjects = 4 - 6 hours;
NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours).

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02934

# LIMS_Drug_ID:
26

# Mechanism_Of_Action:
Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
17257.6000

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1IRP

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA10799

# Pharmacology:
Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00026

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic/anakinra.htm

# Salts:
Not Available

# Secondary_Accession_No:
BIOD00060
BTD00060

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
P18510

# SwissProt_Name:
IL1RA_HUMAN

# Synonyms:
ICIL-1RA
IL-1RN
IL-1ra
IL1 inhibitor
IRAP
Interleukin-1 receptor antagonist protein precursor

# Synthesis_Reference:
Not Available

# Toxicity:
Most common adverse reactions (incidence â‰¥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence >10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis.

# Update_Date:
2013-06-19 20:10:12 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Anakinra

# pKa_Isoelectric_Point:
5.46

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10210771	Vannier E, Kaser A, Atkins MB, Fantuzzi G, Dinarello CA, Mier JW, Tilg H: Elevated circulating levels of soluble interleukin-1 receptor type II during interleukin-2 immunotherapy. Eur Cytokine Netw. 1999 Mar;10(1):37-42.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
12355453	Vamvakopoulos J, Green C, Metcalfe S: Genetic control of IL-1beta bioactivity through differential regulation of the IL-1 receptor antagonist. Eur J Immunol. 2002 Oct;32(10):2988-96.
12817089	Dayer JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford). 2003 May;42 Suppl 2:ii3-10.
17083033	Do H, Vasilescu A, Carpentier W, Meyer L, Diop G, Hirtzig T, Coulonges C, Labib T, Spadoni JL, Therwath A, Lathrop M, Matsuda F, Zagury JF: Exhaustive genotyping of the interleukin-1 family genes and associations with AIDS progression in a French cohort. J Infect Dis. 2006 Dec 1;194(11):1492-504. Epub 2006 Oct 26.
17352828	So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9(2):R28.
17498496	Tang YH, Zhang SP, Liang Y, Deng CQ: [Effects of Panax notoginseng saponins on mRNA expressions of interleukin-1 beta, its correlative factors and cysteinyl-aspartate specific protease after cerebral ischemia-reperfusion in rats] Zhong Xi Yi Jie He Xue Bao. 2007 May;5(3):328-32.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
IL1R1

# Drug_Target_1_GenBank_ID_Gene:
X16896

# Drug_Target_1_GenBank_ID_Protein:
33801

# Drug_Target_1_GeneCard_ID:
IL1R1

# Drug_Target_1_Gene_Name:
IL1R1

# Drug_Target_1_Gene_Sequence:
>1710 bp
ATGAAAGTGTTACTCAGACTTATTTGTTTCATAGCTCTACTGATTTCTTCTCTGGAGGCT
GATAAATGCAAGGAACGTGAAGAAAAAATAATTTTAGTGTCATCTGCAAATGAAATTGAT
GTTCGTCCCTGTCCTCTTAACCCAAATGAACACAAAGGCACTATAACTTGGTATAAAGAT
GACAGCAAGACACCTGTATCTACAGAACAAGCCTCCAGGATTCATCAACACAAAGAGAAA
CTTTGGTTTGTTCCTGCTAAGGTGGAGGATTCAGGACATTACTATTGCGTGGTAAGAAAT
TCATCTTACTGCCTCAGAATTAAAATAAGTGCAAAATTTGTGGAGAATGAGCCTAACTTA
TGTTATAATGCACAAGCCATATTTAAGCAGAAACTACCCGTTGCAGGAGACGGAGGACTT
GTGTGCCCTTATATGGAGTTTTTTAAAAATGAAAATAATGAGTTACCTAAATTACAGTGG
TATAAGGATTGCAAACCTCTACTTCTTGACAATATACACTTTAGTGGAGTCAAAGATAGG
CTCATCGTGATGAATGTGGCTGAAAAGCATAGAGGGAACTATACTTGTCATGCATCCTAC
ACATACTTGGGCAAGCAATATCCTATTACCCGGGTAATAGAATTTATTACTCTAGAGGAA
AACAAACCCACAAGGCCTGTGATTGTGAGCCCAGCTAATGAGACAATGGAAGTAGACTTG
GGATCCCAGATACAATTGATCTGTAATGTCACCGGCCAGTTGAGTGACATTGCTTACTGG
AAGTGGAATGGGTCAGTAATTGATGAAGATGACCCAGTGCTAGGGGAAGACTATTACAGT
GTGGAAAATCCTGCAAACAAAAGAAGGAGTACCCTCATCACAGTGCTTAATATATCGGAA
ATTGAAAGTAGATTTTATAAACATCCATTTACCTGTTTTGCCAAGAATACACATGGTATA
GATGCAGCATATATCCAGTTAATATATCCAGTCACTAATTTCCAGAAGCACATGATTGGT
ATATGTGTCACGTTGACAGTCATAATTGTGTGTTCTGTTTTCATCTATAAAATCTTCAAG
ATTGACATTGTGCTTTGGTACAGGGATTCCTGCTATGATTTTCTCCCAATAAAAGCTTCA
GATGGAAAGACCTATGACGCATATATACTGTATCCAAAGACTGTTGGGGAAGGGTCTACC
TCTGACTGTGATATTTTTGTGTTTAAAGTCTTGCCTGAGGTCTTGGAAAAACAGTGTGGA
TATAAGCTGTTCATTTATGGAAGGGATGACTACGTTGGGGAAGACATTGTTGAGGTCATT
AATGAAAACGTAAAGAAAAGCAGAAGACTGATTATCATTTTAGTCAGAGAAACATCAGGC
TTCAGCTGGCTGGGTGGTTCATCTGAAGAGCAAATAGCCATGTATAATGCTCTTGTTCAG
GATGGAATTAAAGTTGTCCTGCTTGAGCTGGAGAAAATCCAAGACTATGAGAAAATGCCA
GAATCGATTAAATTCATTAAGCAGAAACATGGGGCTATCCGCTGGTCAGGGGACTTTACA
CAGGGACCACAGTCTGCAAAGACAAGGTTCTGGAAGAATGTCAGGTACCACATGCCAGTC
CAGCGACGGTCACCTTCATCTAAACACCAGTTACTGTCACCAGCCACTAAGGAGAAACTG
CAAAGAGAGGCTCACGTGCCTCTCGGGTAG

# Drug_Target_1_General_Function:
Involved in transmembrane receptor activity

# Drug_Target_1_General_References:
10903327	Vigers GP, Dripps DJ, Edwards CK 3rd, Brandhuber BJ: X-ray crystal structure of a small antagonist peptide bound to interleukin-1 receptor type 1. J Biol Chem. 2000 Nov 24;275(47):36927-33.
2530587	Sims JE, Acres RB, Grubin CE, McMahan CJ, Wignall JM, March CJ, Dower SK: Cloning the interleukin 1 receptor from human T cells. Proc Natl Acad Sci U S A. 1989 Nov;86(22):8946-50.
2532321	Chua AO, Gubler U: Sequence of the cDNA for the human fibroblast type interleukin-1 receptor. Nucleic Acids Res. 1989 Dec 11;17(23):10114.
9062193	Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ: Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature. 1997 Mar 13;386(6621):190-4.
9062194	Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW: A new cytokine-receptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature. 1997 Mar 13;386(6621):194-200.
9371760	Huang J, Gao X, Li S, Cao Z: Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12829-32.

# Drug_Target_1_HGNC_ID:
HGNC:5993

# Drug_Target_1_HPRD_ID:
00994

# Drug_Target_1_ID:
622

# Drug_Target_1_Locus:
2q12

# Drug_Target_1_Molecular_Weight:
65403

# Drug_Target_1_Name:
Interleukin-1 receptor type I

# Drug_Target_1_Number_of_Residues:
569

# Drug_Target_1_PDB_ID:
1IRA

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00047	ig
PF01582	TIR

# Drug_Target_1_Protein_Sequence:
>Interleukin-1 receptor type I precursor
MKVLLRLICFIALLISSLEADKCKEREEKIILVSSANEIDVRPCPLNPNEHKGTITWYKD
DSKTPVSTEQASRIHQHKEKLWFVPAKVEDSGHYYCVVRNSSYCLRIKISAKFVENEPNL
CYNAQAIFKQKLPVAGDGGLVCPYMEFFKNENNELPKLQWYKDCKPLLLDNIHFSGVKDR
LIVMNVAEKHRGNYTCHASYTYLGKQYPITRVIEFITLEENKPTRPVIVSPANETMEVDL
GSQIQLICNVTGQLSDIAYWKWNGSVIDEDDPVLGEDYYSVENPANKRRSTLITVLNISE
IESRFYKHPFTCFAKNTHGIDAAYIQLIYPVTNFQKHMIGICVTLTVIIVCSVFIYKIFK
IDIVLWYRDSCYDFLPIKASDGKTYDAYILYPKTVGEGSTSDCDIFVFKVLPEVLEKQCG
YKLFIYGRDDYVGEDIVEVINENVKKSRRLIIILVRETSGFSWLGGSSEEQIAMYNALVQ
DGIKVVLLELEKIQDYEKMPESIKFIKQKHGAIRWSGDFTQGPQSAKTRFWKNVRYHMPV
QRRSPSSKHQLLSPATKEKLQREAHVPLG

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-17

# Drug_Target_1_Specific_Function:
Receptor for interleukin-1 alpha (IL-1A), beta (IL-1B), and interleukin-1 receptor antagonist protein (IL-1RA). Binding to the agonist leads to the activation of NF-kappa-B. Signaling involves formation of a ternary complex containing IL1RAP, TOLLIP, MYD88, and IRAK1 or IRAK2

# Drug_Target_1_SwissProt_ID:
P14778

# Drug_Target_1_SwissProt_Name:
IL1R1_HUMAN

# Drug_Target_1_Synonyms:
CD121a antigen
IL-1R- alpha
IL-1R-1
IL-1RT1
Interleukin-1 receptor type I precursor
p80

# Drug_Target_1_Theoretical_pI:
7.89

# Drug_Target_1_Transmembrane_Regions:
337-356

#END_DRUGCARD DB00026
